TickerTalks
Browse all tickers →
TickerTalks›$TVTX
TVTVTX

Travere Therapeutics, Inc.

$TVTX·$5.8B·Biotechnology·Healthcare
$59.54-1.8%YTD+53.0%1Y+148.3%
Price updated 14m ago·X counts updated 12d ago
TVTVTX
$TVTXTravere Therapeutics, Inc.
$59.54-1.79%56 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $TVTX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

56X posts · last 7 days
Sep 7Sep 13
Bullish sentimentAI analysisGenerated by AI from underlying data40 posts analyzed · as of 2026-08-11

Travere Therapeutics posters cheer strong FILSPARI launch — US net product sales +96% YoY to $141M, 2,012 new PSFs received in Q2, and pegtibatinase HARMONY Phase 3 enrollment ongoing with 2H27 topline. JPMorgan upgrade with $90 PT and continued analyst PT raises heading into August. In-licensing of civorebrutinib expands the pipeline. Sentiment is decisively bullish.

Read what X is saying about $TVTX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $TVTX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-25

The move is getting stronger, with heavier trading behind it.

FILSPARI launch running 96% YoY US net sales — CEO transition plus JPMorgan $90 PT.

Travere Therapeutics is a rare-disease specialty pharma running FILSPARI (sparsentan) for FSGS/IgA Nephropathy plus a growing pipeline including pegtibatinase (HARMONY Phase 3). The equity has 2.5x'd t12m as FILSPARI's commercial launch has accelerated dramatically.

  • The commercial ramp is exceptional: FILSPARI US net product sales grew 96% YoY to $141M in Q2, with 2,012 new prescription-start forms received — that's specific dollar-quantified prescribing acceleration. Q2 EPS missed by 175%, but the last four prints have been mixed on the P&L while revenue accelerates hard.
  • The CEO transition is a specific governance event: Eric Dube stepping down effective December 1 with Bradley Campbell taking over — that's a planned transition, not a distress signal. JPMorgan's $90 PT upgrade plus analyst PT raises heading into August frame the analyst view.

Oct 29 earnings needs another beat above the recent revenue-acceleration trend plus specific FILSPARI PSF and net-sales commentary to keep the acceleration at 83% of the 52-week range. Beat plus positive pegtibatinase HARMONY Phase 3 enrollment update extends the run; a competitive-launch concern or a walked-back FY guide is the invalidation. The civorebrutinib in-licensing expands the pipeline optionality.

Agrees with X sentimentX posters correctly frame the FILSPARI US net sales +96% YoY plus 2,012 new PSFs and JPMorgan $90 PT upgrade. The mechanics agree — this is a real commercial-launch story.

What to watch: Oct 29 Q3 earnings — FILSPARI US net product sales, prescription starts, and any pegtibatinase HARMONY Phase 3 update. Beat plus visible ramp continuation extends the run; a walked-back FY guide is the invalidation.

On the calendar: 2026-10-29 — Q3 2026 earnings

Read the AI verdict on $TVTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Rare disease biotech with FILSPARI (sparsentan) approved for IgA nephropathy; also bile acid and metabolic disorder drugs.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TVTX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver; MRNA's personalized cancer vaccine (melanoma Phase 3 Oct readout) has extended a 137% monthly run. IBB +42% T12M reflects broad RNA-medicine and gene-editing multiple re-rating; GLP-1 pipeline names (ALT, VKTX, KLRA) are the secondary near-term catalyst cohort.

What this means for $TVTX

Neutral — FILSPARI (sparsentan) for IgA nephropathy and FSGS is a commercial rare kidney disease drug; no intersection with mRNA oncology or GLP-1 themes; pegtibatinase for homocystinuria adds pipeline optionality.

Top industry ETF

$IBBiShares Biotechnology ETF
+23.3%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-236.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-13.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
9.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
94.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
3.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.37$-0.13-174.8%
Q1 2026May 4, 2026$-0.39$-0.30-30.0%
Q4 2025Feb 19, 2026$0.03$0.030.0%
Q3 2025Oct 30, 2025$0.28$-0.31+190.3%
Next earningsThu, Oct 29·consensus EPS $0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$127.2M+55.6%79.0%-29.0%$-0.40$-62.5M
Q4 FY25$129.7M+73.4%98.0%-25.0%$-0.24$61.1M
Q3 FY25$164.9M+162.1%99.0%15.1%$0.29$14.2M
Q2 FY25$114.4M+111.5%98.7%-11.1%$-0.14$4.7M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$724.1M$691.0M – $781.9M-$0.03-$0.06 – $0.0411
FY27$1.1B$978.5M – $1.3B$3.16-$0.23 – $7.0011
FY28$1.4B$1.1B – $1.6B$4.52$2.26 – $7.6411
FY29$1.6B$1.4B – $1.9B$4.65$3.74 – $5.735
FY30$1.9B$1.6B – $2.3B$5.62$4.53 – $6.945

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.83%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+36.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 90.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.065-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 17Peter HeermaEVP, CHIEF COMMERCIAL OFFICER8.3K sh$539KSellSep 16William E. RoteChief Research Officer112.8K sh$7.1MSellSep 16Peter HeermaEVP, CHIEF COMMERCIAL OFFICER172.7K sh$11.0MSellSep 15William E. RoteChief Research Officer96.2K sh$6.0MSellSep 15Peter HeermaEVP, CHIEF COMMERCIAL OFFICER102.2K sh$6.4MSellSep 15Jula InrigEVP, Head of R&D & CMO44.7K sh$2.8MSellSep 15Elizabeth E ReedChief Legal Officer and GC37.5K sh$2.3MSellSep 10Jeffrey A MecklerDirector20.0K sh$1.3MSellSep 2Christopher R. ClineCFO642 sh$43KSellAug 18Gary A LyonsDirector5.0K sh$317K
1–10 of 23
+ 31 other (18 exempts · 12 awards · 1 gift) in window

See when $TVTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeSep 218-K — Item 5.02: Officer or director change
AI summary

Travere Therapeutics, Inc. announced a planned CEO succession on September 21, 2026: incumbent President and CEO Eric Dube, Ph.D. will step down effective December 1, 2026, continuing as Executive Advisor through February 15, 2027. Bradley L. Campbell, 51, has been appointed as successor President and CEO effective December 1, 2026; Campbell previously served as CEO of Amicus Therapeutics from August 2022 until its acquisition by BioMarin in April 2026 and brings over 25 years of biopharma experience. This is an orderly, planned leadership transition with a structured advisory handoff, reducing succession risk.

8-KOfficer or director changeJul 98-K — Item 5.02: Officer or director change
AI summary

Travere Therapeutics disclosed on July 6, 2026 that Chief Accounting Officer and Principal Accounting Officer Sandra Calvin will retire following the filing of the company's annual Form 10-K, expected in February 2027. John Torell, CFA, CPA, current VP, Controller (at TVTX since 2021), is expected to succeed her in both roles, with board appointment expected before the Retirement Date to ensure an orderly transition. Planned multi-month leadership transition with a named internal successor; low operational disruption risk.

8-KOfficer or director changeJun 168-K — Item 5.02: Officer or director change
AI summary

Travere Therapeutics Chief Research Officer William Rote, Ph.D. provided notice on June 12, 2026 of his retirement effective February 17, 2027, the 10-year anniversary of his employment; he will remain in his current role and assist with transition through the Retirement Date. No successor CRO is named in the excerpt. Orderly planned departure with 8+ months of notice; the lengthy notice period suggests internal succession planning is underway, though the CRO role is material for a company mid-development on civorebrutinib and other pipeline assets.

8-KMaterial agreementJun 28-K — Item 1.01: Material agreement
AI summary

Travere Therapeutics entered a license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. on June 1, 2026 under which Everest grants Travere exclusive, royalty-bearing rights to develop and commercialize civorebrutinib (EVER001), a covalent reversible BTK inhibitor, in all fields across all countries outside China and certain East/Southeast Asian territories. Travere gains rights to make, import, distribute, sell, and develop the compound globally ex-Asia, with rights including a sublicense to third-party IP. Financial terms (upfront, milestones, royalties) are not disclosed in the excerpt. Material in-licensing deal — civorebrutinib adds a BTK inhibitor to Travere's pipeline, complementing its rare kidney disease focus, likely funded by the concurrent $525M convertible note raise.

8-KOfficer or director changeMay 218-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Travere Therapeutics held its 2026 Annual Meeting at which stockholders approved an amendment to the 2018 Equity Incentive Plan increasing the authorized share pool by 3,000,000 shares; this is disclosed under Item 5.02 as a compensatory arrangement approval. Item 5.07 covers the broader Annual Meeting voting results. Additional annual meeting proposals beyond the equity plan are described in the proxy but their vote outcomes are not fully detailed in the excerpt. The 3M share addition provides equity compensation runway; mildly dilutive.

8-KMaterial agreementMay 118-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 3.02: Unregistered equity sale · Item 8.01: Other event
AI summary

Travere Therapeutics completed a $525 million registered underwritten offering of 0.50% Convertible Senior Notes due May 15, 2032 on May 11, 2026, including $50M from full exercise of the underwriters' overallotment (underwriters: J.P. Morgan, Jefferies, Leerink Partners). Notes are redeemable at Travere's option from May 21, 2029 onward if the stock exceeds 130% of the conversion price; settlement in cash, shares, or a combination. Items 2.03/3.02 cover the debt creation and private placement aspects; Item 8.01 likely covers a concurrent capped call transaction to limit dilution above the conversion premium. A large-scale capital raise at low cost of debt — the $525M will fund pipeline development including the Everest BTK inhibitor license and commercial FILSPARI activities.

424B5Prospectus supplement (offering)May 7424B5
AI summary

Travere Therapeutics filed a 424B5 prospectus supplement for $475 million of 0.50% Convertible Senior Notes due May 15, 2032 at 100% issue price (with $50M underwriter greenshoe option). Conversion is permitted under specified stock price and trading triggers; notes are redeemable from May 21, 2029 onward if the stock exceeds 130% of the conversion price; settlement in cash, shares, or a combination at Travere's option. This is the pricing prospectus for the convertible offering, which was ultimately upsized to $525M following full exercise of the overallotment (see Job 45). The offering provides long-term capital at a low 0.50% coupon with dilution contingent on stock performance above the conversion premium.

424B5Prospectus supplement (offering)May 5424B5
AI summary

Travere Therapeutics filed an earlier 424B5 prospectus supplement for $400 million (with $60M greenshoe option) of convertible senior notes due 2032; the coupon and conversion price fields appear as blank placeholders in the excerpt, indicating this was a preliminary or term-pending filing before pricing was finalized. This preliminary prospectus was superseded by the final $475M pricing prospectus (Job 49) and the ultimately closed $525M offering (Job 45). Administrative/preliminary filing for Travere's convertible note offering process.

+ 16 other (6 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell?defenseworld.net·1d agoTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Ggurufocus.com·2d agoTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosisbusinesswire.com·2d agoTravere Therapeutics Announces Planned Chief Executive Officer Transitionbusinesswire.com·4d agoInsider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stockdefenseworld.net·5d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $TVTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport